All In Biotech

Drug Trial Radar · NCT06198907

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)

Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

69

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Dizal Pharmaceuticals
First posted
Jan 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

  • GolidocitinibDrug

    Daily dosing of golidocitinib

  • SintilimabDrug

    Sintilimab, 200mg, intravenous, every 3 weeks.

  • platinum doublet chemotherapyDrug

    Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) (cohort1)Time frame: through study completion, an average of 1 year
  2. Progression-free survival (PFS) (cohort2)Time frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.